Analysts expect the company to post earnings of $4.76, representing a 10.4% drop from the corresponding period of the previous year. Revenue is expected to rise 4% to $9.46B. Over the last 3 months, ...

Altimmune, Inc. closed a $75 million direct offering to fund Phase 3 pemvidutide trials for MASH. Learn more about ALT stock ...